40 results about "Enzyme family" patented technology

A process is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family 7 (CE-7) based on the conserved structural features. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided.

A process is provided for producing target concentrations of peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity under conditions where control of reaction pH by selection of buffer concentration and concentration of perhydrolase and reactants produces a targeted concentration of peroxycarboxylic acids. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family 7 (CE-7) based on the conserved structural features. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided, as are corresponding methods of use.

Purified cellobiohydrolase I (glycosyl hydrolase family 7 (Cel7A) enzymes from Penicillium funiculosum demonstrate a high level of specific performance in comparison to other Cel7 family member enzymes when formulated with purified EIcd endoglucanase from A. cellulolyticus and tested on pretreated corn stover. This result is true of the purified native enzyme, as well as recombinantly expressed enzyme, for example, that enzyme expressed in a non-native Aspergilllus host. In a specific example, the specific performance of the formulation using puriified recombinant Cel7A from Penicillium funiculosum expressed in A. awamori is increased by more than 200% when compared to a formulation using purified Cel7A from Trichoderma reesei.

The invention provides a beta-glucosaccharase gene for coding a glycosyl hydrolase family 1 and an application thereof. The nucleotide sequence of the beta-glucosaccharase gene is shown in SEQ ID NO:1, the nucleotide sequence of beta-glucosaccharase S-bgl4 coded by the gene is shown in SEQ ID NO:2, and the beta-glucosaccharase S-bgl4 can be applied to decomposition of cellobiose.

A process is provided for producing target concentrations of peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity under conditions where control of reaction pH by selection of buffer concentration and concentration of perhydrolase and reactants produces a targeted concentration of peroxycarboxylic acids. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family 7 (CE-7) based on the conserved structural features. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided, as are corresponding methods of use.

The invention discloses an OcPP2C44 gene separated and cloned from rice deoxyribonucleic acid (DNA) fragments and related to rice stress resistance. The protein of the genetic code contains protein phosphatase family conservative catalytic structural domain and is a member of a PP2C type of the gene family. The OsPP2C44 gene is performed with inducible expression of high salinity, low temperature, high temperature and abscisic acid (ABA), and overexpression OsPP2C44 can improve osmotic stress resistance capability of rice during seedling stage and is related to rice stress resistance. The rice gene of the OcPP2C44 gene has obvious response to adverse situation, can be applied to plant stress resistance breeding, and improves stress resistance of plants.

The invention discloses a miniaturization cucumber plant associated protein and a coding gene thereof and an application thereof. An amino acid sequence of the protein is shown as a sequence table 2, which belongs to AAA ATP enzyme family, and is related with microtubule associated protein; the coding gene of the protein has a base sequence shown as a sequence table 1, if the mutation is generated on the base sequence, such as cytosine (C) with 1058 bp bit is substituted by thymidine (T), serine (Ser) with 353 bit for coding the protein is changed to phenylalanine (Phe), the protein inhibits the normal growth of the microtubule cell, the microtubule cytoskeleton is lost, the arrangement is abnormal, concretely, the plant phenotype is plant miniaturization, the height of the mutant plant is about 20% of the height of a normal wild type plant, the fruit length is about 10% of the length of normal wild type fruit, and the leaves and the seeds are obviously shortened. The application of the protein and the coding gene can create condition for cucumber strain-type improvement and cross breeding or exploitation of transgene plants.

The present invention is directed to the discovery of a novel family of enzymes designated herein as mRNA interferases that exhibit endoribonuclease activity. The novel finding of the present inventors, therefore, presents new applications for which mRNA interferase nucleic and amino acid sequences, and compositions thereof may be used to advantage. The invention also encompasses screening methods to identify compounds / agents capable of modulating mRNA interferase activity and methods for using such compounds / agents. Also provided is a kit comprising mRNA interferase nucleic and / or amino acid sequences, mRNA interferase activity compatible buffers, and instruction materials.

A gene umcel5A coding cellulase features that it contains the nucleoside sequence shown by SEQ ID No.2 or its homologous sequences. The cellulase coded by said gene and its application in degradating cellulose are also disclosed.

The invention is relative to the various uses of a novel enzyme family, referred to as THYX, capable of catalyzing the synthesis of thymidine 5'-monophosphate in the absence of an active thymidylate synthase enzyme (ThyA). The invention also relates to reaction media for the thymidylate synthase activity of a THYX polypeptide as well as screening methods implementing said reaction media, as well as kits for implementing such methods.

The invention discloses streptomyces thermoviolaceus chitinase (GH19 family), as well as a preparation method and application of streptomyces thermoviolaceus chitinase. According to the method, a chitinase gene sequence in streptomyces thermoviolaceus can be obtained by utilizing a gene synthesis method according to the codon preference of pichia pastoris, and the optimized nucleotide sequence isas shown in SEQ ID NO.2. The optimized chitinase coding gene is efficiently secreted and expressed by further utilizing a pichia pastoris expression system to obtain the streptomyces thermoviolaceus chitinase (GH19 family) having an amino acid sequence as shown in SEQ ID NO.1. The streptomyces thermoviolaceus chitinase (GH19 family) has relatively high hydrolytic activity for chitosan primer withlow degree of deacetylation, 1mL of crude enzyme (the content of protein is about 0.30mg) generated by fermentation of a shake flask has the hydrolysis ability for degrading 0.5g of chitosan, and theefficiency is improved by over 300 times theoretically since about 100mg of commercial cellulose is required for degrading the same amount of chitosan. The streptomyces thermoviolaceus chitinase has excellent industrial application prospect.

The invention provides application of delinearized ubiquitin enzyme family with sequence similarity 105, member B (FAM105B) in liver cancer diagnosis, treatment and prognosis judgment. Various technical detection finds that the FAM105B is highly expressed in a liver cancer cell line and liver cancer tissue, and high expression of the FAM105B is positively correlated with adverse clinical pathological characteristics of a hepatocellular carcinoma (HCC) patient, a poor postoperative overall survival rate and a poor tumor-free survival rate; it is proved that high expression of the FAM105B in theliver cancer tissue is an independent risk factor influencing long-term survival of liver cancer patients; an in-vitro hepatoma cell model constructed by gene knockout and overexpression techniques finds that the FAM105B can promote the proliferation, migration and invasion abilities and epithelial-mesenchymal transition of hepatoma cells. The research findings indicate that the delinearized ubiquitin enzyme FAM105B can be used as a marker for developing a new liver cancer diagnosis and prognosis judgment kit, and an effective target is provided for preparing liver cancer treatment medicines.

The invention relates to a saccharase gene of a coding sugar-based hydrolytic ferment family 32 and applications thereof. The invention is characterized by comprising a nucleotide sequence of SEQ ID NO: 1 and or a functional-equivalent variant thereof. The invention comprises the saccharase (SEQ ID NO:2) of the gene or the functional-equivalent variant code thereof and the applications of the saccharase in degrading cane sugar.

The present invention relates to a method for producing highly-concentrated L-amino acid and riboflavin simultaneously, and a microorganism for simultaneously producing L-amino acid and riboflavin. Specifically, the present invention relates to a modified microorganism for producing L-lysine or L-threonine, and riboflavin simultaneously, wherein the microorganism belonging to Corynebacterium sp. capable of producing L-lysine or L-threonine is modified by enhancing the activity of an enzyme family expressed by a rib operon which contains riboflavin biosynthesis gene family. Also, the present invention relates to a method for the simultaneous production of L-lysine or L-threonine, and riboflavin using the modified microorganism, and relates to a formulation or granular formulation, feed, and feed additive, containing L-lysine or L-threonine, and riboflavin produced from a culture medium of the modified microorganism.

The present invention is directed to the discovery of a novel family of enzymes designated herein as mRNA interferases that exhibit endoribonuclease activity. The novel finding of the present inventors, therefore, presents new applications for which mRNA interferase nucleic and amino acid sequences, and compositions thereof may be used to advantage. The invention also encompasses screening methods to identify compounds / agents capable of modulating mRNA interferase activity and methods for using such compounds / agents. Also provided is a kit comprising mRNA interferase nucleic and / or amino acid sequences, mRNA interferase activity compatible buffers, and instruction materials.

Clostridium novyi is an obligate anaerobe that can infect hypoxic regions within experimental tumors. We found that mice bearing large, established tumors were often cured when treated with C. novyi plus a single dose of liposomal doxorubicin. The secreted factor responsible for this phenomenon was identified and, surprisingly, proved to be a member of the lipase family. The gene encoding this protein, called liposomase, has the potential to be incorporated into diverse therapeutic methods to deliver specifically a variety of chemotherapeutic agents to tumors.

The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3α ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products.

The invention discloses combined use of a tetravalent cisplatin predrug and a biological reducing drug. The structural f formula of the tetravalent cisplatin predrug is represented by a formula (I) (shown in description), wherein m represents 0-1000, n represents 1-1000, and I represents 1-1000. The tetravalent cisplatin predrug is loaded with a biological reducing drug, namely tirapazamine, a cisplatin anti-cancer drug is released through degradation in a tumor microelement,and the high expression of enzyme families of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) in cancer cells can be induced, so that the oxygen consumption rate of the cancer cells is increased, the pesticide effect of the biological reducing drug, namely tirapazamine is further improved, and the treatment effect of the whole cancer treatment process can be improved through synergistic treatment.

It is an aim of the present invention to provide inhibitors of human diphtheria toxin-like ADP-ribosyltransferases, such as ARTD10, for use as a medicine. It is another aim of the invention to provide compounds for use as human mono-ADP-ribosyltransferase (mARTD) inhibitors in vitro. In the present invention, it has been discovered that human ARTD10, which belongs to an enzyme family linked to cancer biology, can be specifically inhibited by the benzamide comprising compounds disclosed in the invention, such as 4,4′-oxydibenzamide.

The present invention relates to compositions that can be used in hydrolyzing biomass such as compositions comprising a polypeptide having glycosyl hydrolase family 61 / endoglucanase activity, methods for hydrolyzing biomass material, and methods for reducing viscosity of biomass mixture using a composition comprising a polypeptide having glycosyl hydrolase family 61 / endoglucanase activity.

The invention provides esterases and a coding gene and an application thereof, and belongs to the technical field of genetic engineering and enzyme engineering. A gene for coding the esterases E31-4922 is obtained through screening and cloning from Antarctic soil; through researching expression proteins of the esterases, the inventor finds that the esterases show high degradation activity on short-chain esters, the optimum pH is 7.5, and the esterases stably exist in the pH range being 7.0-8.0; the optimum enzyme activity temperature is 80 DEG C, and the esterases maintain vitality being overthan 80% in the range of 60-90 DEG C; the esterases are thermally-stable esterases, and show higher tolerance for high temperature environment being over than 60 DEG C; and the esterases have important significance in enriching the family members of the esterases particularly the family members of high temperature resistant esterases.

The invention provide a group of cysteine hydrolases with (+) gamma lactam resolution activity. The cysteine hydrolases come from 13 microorganism species, and have three common conserved structural domains: the conserved structural domain I: *A(V / M / R / G / T)L(V / H / I)L(V / I)L(V / I)V(N / E / D)*(H / I)DM(L / V / I)Q, the conserved structural domain II: *S(G / D / N)*F(W / Y)*, the conserved structural domain III: *(F / V / M)V(A / C / M / T)G*T(A)N(E / H / D / A)*C(G / A / D / P), wherein * stands for any amino acid residue, and the amino acids in the brackets stand for possible amino acid residues at the same amino acid residues. The invention also provides coding genes of the above cysteine hydrolases, and applications of the above cysteine hydrolases in resolution of racemate gamma lactam.

The present invention includes novel derivatives, analogs, and intermediates of the natural products radicicol, pochonins, pochoximes, and their syntheses. The present invention also provides a pharamceutical composition comprising the present compound and the use of the compound as inhibitors of kinases and of the enzyme family known as heat shock protein 90 (HSP90).

The invention discloses an application of glutathione mercaptotransferase as a detoxifying enzyme for preventing and treating duck liver injury caused by AFB1, and provides an application of GST and GST3 as target enzymes for preventing and treating animal liver injury caused by AFB1 by testing 10 GST in a duck GSTs enzyme family and screening out GST and GST3 with detoxifying effects. The glutathione mercaptotransferase (GST or GST3) provided by the invention can effectively inhibit or relieve AFB1-induced liver toxicity of ducklings, and is mainly related to the metabolism of catalyzing AFBO to generate nontoxic AFBO-GSH. The GST and the GST3 can be used as drugs for treating duck liver injury caused by AFB1 and provide new target genes for development of novel feed additives.

Provided are certain glycosyl hydrolase family 3 (GH3) beta-xylosidases engineered to acquire beta-glucosidase activities. Provided also are compositions comprising such multi-functional GH3 enzymes and methods of use or industrial applications thereof.

The invention discloses the application of a soybean E3 ubiquitin ligase family gene GmRNF1a. Soybean GmRNF1a protein coding gene GmRNF1a, its nucleotide sequence is: SEQ ID NO.1. The constructed plant overexpression vector pMDC83‑GmRNF1a was heterologously expressed in the wild type of Arabidopsis, and it was found that the maturation process of the transgenic plants was significantly accelerated, and the fruit pods burst earlier. It shows that the gene can be introduced into plants as a target gene, and by inhibiting the expression of GmRNF1a gene, it can inhibit the early bursting of fruit pods of transgenic plants. It can be seen that the soybean GmRNF1a protein coding gene GmRNF1a of the present invention can be used in promoting early maturity of plants through genetic engineering and regulating the bursting time of plant pods.

The present invention relates to the control of infestation of pests by inhibiting or reducing the expression of genes of the family of chitin synthase. The invention further provides methods and compositions for controlling pests by feeding them with one or more double-strand RNA molecules provides by the present invention. The invention further describes a method of obtaining transgenic plants that express double-strand RNA molecules. The present invention is preferably used for cotton-plants.